

No: 04../TKKT

Ho Chi Minh City, January 20., 2025

To: - State Securities Commission of Vietnam
- Hanoi Stock Exchange

Subject: Explanation of the consolidated business performance results for Quarter and the full year 2024 with a discrepancy of more than 10% compared to the same period in 2023

Pursuant to the regulations under Circular 96/2020/TT-BTC on public disclosure in the securities market, Mekophar Chemical and Pharmaceutical Joint Stock Company (Stock code: MKP) provides an explanation of the consolidated business performance results for Quarter and the full year 2024 with a difference of more than 10% compared to the same period in 2023 as follows::

1. Results for Quarter 2024 compared to Quarter 2023 (the consolidated Report):

Indicator	Quarter 2024	Quarter 2023	Difference	(%)
Revenue	244.810.872.705	253.207.284.671	- 8.396.411.966	-3,3%
Cost of Goods Sold	179.109.879.226	174.834.983.734	4.274.895.492	2,4%
Selling Expenses	26.250.533.363	28.023.835.275	- 1.773.301.912	-6,3%
Administrative Expenses	40.414.076.224	51.604.134.718	- 11.190.058.494	-21,7%
Financial Revenue	38.149.948.399	14.264.956.967	23.884.991.432	167,4%
Net Profit After Tax	28.885.148.995	17.654.619.937	11.230.529.058	63,6%

Reason: The net profit after tax for Quarter 2024 increased by 63.6% mainly due to income from financial investments.

2. Results for 2024 compared to 2023 (the consolidated Report):

Indicator	Quarter 2024	Quarter 2023	Difference	(%)
Revenue	919.583.349.082	904.838.743.436	14.744.605.646	1,6%
Cost of Goods Sold	671.520.897.763	637.368.901.371	34.151.996.392	5,4%
Selling Expenses	110.356.307.641	108.591.717.591	1.764.590.050	1,6%
Administrative Expenses	144.878.523.920	151.740.435.938	- 6.861.912.018	-4,5%
Financial Revenue	66.436.618.579	24.884.010.729	41.552.607.850	167,0%
Net Profit After Tax	42.263.025.646	25.114.127.514	17.148.898.132	68,3%

Reason: The net profit after tax for 2024 increased by 68.3% mainly due to income from financial investments.

This information has been published on the Company's website at: <https://mekophar.com/> in the "Investor Relations" section.

The Company affirms that the information provided is accurate and takes full responsibility for the disclosed content.

Recipient:

- As above
- Archive



GENERAL DIRECTOR *[Signature]*

Pharm. Huỳnh Thị Lan